Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease

Neurology

Volumn 64, Issue 9, 2005, Pages 1563-1572

  Fox, N C ^a   Black, R S ^b   Gilman, S ^c   Rossor, M N ^a   Griffith, S G ^d   Jenkins, L ^b   Koller, M ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PFIZER INC   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; IMMUNOGLOBULIN G; QS 21; SODIUM CHLORIDE; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); ANTIBODY; PEPTIDE FRAGMENT; PLACEBO; VACCINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; BRAIN VENTRICLE; BRAIN VENTRICLE DILATATION; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HIPPOCAMPUS; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ACTIVE IMMUNIZATION; ATROPHY; BLOOD; BRAIN CORTEX; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; LATERAL BRAIN VENTRICLE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODIES; ATROPHY; CEREBRAL CORTEX; CEREBROSPINAL FLUID; COGNITION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HIPPOCAMPUS; HUMANS; IMMUNOTHERAPY, ACTIVE; LATERAL VENTRICLES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLACEBOS; TREATMENT OUTCOME; VACCINES;

EID: 18144415471     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000159743.08996.99     Document Type: Article

References (38)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259.
2. Scarpini ESPFH. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2004;2:539-547.
3. Black SE. The search for diagnostic and progression markers in AD: so near but still too far? Neurology 1999;52:1533-1534.
4. Jack CR Jr, Slomkowski M, Gracon S, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003;60:253-260.
5. Jack CR Jr, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004;62:591-600.
6. Ashburner J, Csernansky JG, Davatzikos C, Fox NC, Frisoni GB, Thompson PM. Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol 2003;2:79-88.
7. Matthews B, Siemers ER, Mozley PD. Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease. Am J Geriatr Psychiatry 2003;11:146-159.
8. Mani RB. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med 2004;23:305-314.
9. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995;16:271-278.
10. Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 2002;99:4703-4707.
11. Mortimer JA, Gosche KM, Riley KP, Markesbery WR, Snowdon DA. Delayed recall, hippocampal volume and Alzheimer neuropathology: findings from the Nun Study. Neurology 2004;62:428-432.
12. Orgogozo J-M, Gilman S, Dartigues J-F, et al. Subacute meningoen-cephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003;61:46-54.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
14. Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 1997;53:15-25.
15. Whitwell JL, Crum WR, Watt HC, Fox NC. Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. AJNR Am J Neuroradiol 2001;22:1483-1489.
16. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imag 1997;16:623-629.
17. Freeborough PA, Woods RP, Fox NC. Accurate registration of serial 3D MR brain images and its application to visualizing change in neurodegenerative disorders. J Comput Assist Tomogr 1996;20:1012-1022.
18. Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J. A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage 1995;2:89-101.
19. Duvernoy HM. The human hippocampus. 2nd ed. Heidelberg: Springer-Verlag, 1998.
20. Watson C, Andermann F, Gloor P, et al. Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology 1992;42:1743-1750.
21. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease. Arch Neurol 2000;57:339-344.
22. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 2005;64:94-101.
23. O'Brien BJ, Paling S, Barber R, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2004;56:1386-1388.
24. Wang D, Chalk JB, Rose SE, et al. MR image-based measurement of rates of change in volumes of brain structures. Part II: application to a study of Alzheimer's disease and normal aging. Magn Res Imag 2002;20:41-48.
25. Shear PK, Sullivan EV, Mathalon DH, et al. Longitudinal volumetric computed tomographic analysis of regional brain changes in normal aging and Alzheimer's disease. Arch Neurol 1995;52:392-402.
26. Silbert LC, Quinn JF, Moore MM, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003;61:487-492.
27. Du AT, Schuff N, Kramer JH, et al. Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology 2004;62:422-427.
28. Mori E, Lee K, Yasuda M, et al. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Ann Neurol 2002;51:209-214.
29. Chan D, Janssen JC, Whitwell JL, et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet 2003;362:1121-1122.
30. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177. Letter.
31. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003;9:448-452.
32. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussá F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004;14:11-20.
33. Masliah E, Hansen L, Adame A, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer's disease. Neurology 2005;64:129-131.
34. Bussiere T, Friend PD, Sadeghi N, et al. Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease. Neuroscience 2002;112:75-91.
35. Colle MA, Duyckaerts C, Laquerriere A, et al. Laminar specific loss of isocortical presenilin 1 immunoreactivity in Alzheimer's disease. Correlations with the amyloid load and the density of tau-positive neurofibrillary tangles. Neuropathol Appl Neurobiol 2000;26:117-123.
36. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2003;2:506-511.
37. Hamano T, Yoshimura M, Yamazaki T, et al. Amyloid beta-protein (A beta) accumulation in the leptomeninges during aging and in Alzheimer disease. J Neuropathol Exp Neurol 1997;56:922-932.
38. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-613.